OCUL
What one share of Ocular Therapeutix holds
Pharmaceutical Preparations
We are an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI, also known as OTX-TKI, our investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on our ELUTYX proprietary bioresorbable hydrogel-based formulation technology.
Ocular Therapeutix’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.24 |
|---|---|
| Profit | −$1.41 |
| Capex (buildings and equipment) | $0.08 |
| Free cash flow | −$1.19 |
| Cash and investments | $2.73 |
| Debt | $0.33 |
| Book value | $2.37 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.08 | −$1.80 | $0.08 | −$1.45 | — | $2.08 |
| 2017 | $0.07 | −$2.20 | $0.29 | −$2.04 | — | $0.88 |
| 2018 | $0.05 | −$1.57 | $0.05 | −$1.34 | — | $0.86 |
| 2019 | $0.09 | −$1.91 | $0.05 | −$1.76 | — | −$0.07 |
| 2020 | $0.29 | −$2.56 | $0.01 | −$0.90 | — | $1.00 |
| 2021 | $0.53 | −$0.98 | $0.01 | −$0.81 | — | $1.15 |
| 2022 | $0.62 | −$0.97 | $0.04 | −$0.77 | — | $0.46 |
| 2023 | $0.68 | −$1.02 | $0.07 | −$0.89 | — | $0.79 |
| 2024 | $0.40 | −$1.22 | $0.01 | −$0.86 | — | $2.00 |
| 2025 | $0.28 | −$1.42 | $0.06 | −$1.16 | — | $3.03 |